Background: Epidemiologic analysis of family data on blood pressure (BP) is often compromised by the effects of antihypertensive medications. A review of numerous clinical trials that investigated the effects of BPlowering medications is summarized here.
H
ypertension is a common risk factor for coronary heart disease, stroke, congestive heart failure, end-stage kidney disease, and peripheral vascular disease. 1, 2 Hypertension affects about one-quarter of adults in the United States, with estimates from as low as 14% in Hispanics, 24% in whites, 28% in African Americans, and up to three-quarters of African Americans of age group 65 to 74 years. 3 Many studies have been performed on the epidemiologic and genetic control of hypertension. [3] [4] [5] [6] [7] Unfortunately, the use of antihypertensive medications by participants in many of these studies confounds their measured blood pressure (BP). It is believed that predicting the original (pretreatment) BP will yield a more valid measurement for studying the genetic causes of hypertension. A few approaches have already been pursued to correct BP measurements in participants treated with antihypertensive medications. A nonparametric algorithm by ranking (the adjusted) BP was implemented by Levy et al 8 in the Framingham Heart Study. Hunt et al 7 have used three methods to compare corrected BP to measured BP, including the exclusion of all medicated individuals from the analysis or using their measured medicated BPs, the use of a threshold method assigning a fixed BP (140/90 mm Hg) for all medicated participants, and a random assignment of systolic BP between 140 and 160 mm Hg together with a random assignment of diastolic BP between 90 and 100 mm Hg. They concluded that excluding medicated measurements or use of uncorrected BP both lowered lod (logarithm of the odds) score results as compared to correcting BP. Cui et al 9 corrected the medicated BP by adding an arbitrary 10 mm Hg and 5 mm Hg to systolic and diastolic BP, respectively, according to a publication on clinical trials. 10 They also tested the methods of Hunt et al. 7 As a result of correcting the BP, both genetic and shared environmental variance components were shown to have increased. They reported that excluding the participants on antihypertensive medications resulted in a decrease of the genetic variance component. They also created an arbitrary three-step increment for correcting for the use of one, two, and three medications by an average of 10 mm Hg for systolic BP and 5 mm Hg for diastolic BP. As Hunt et al 7 reported, they also found that excluding medicated measurements leads to information loss. On the other hand, uncorrected BP obscured the relationship among phenotypes and genotypes.
Correcting BP with antihypertensive medication is a difficult task, complicated by different medications used by different participants, by combination drug therapies used by some individuals, and by any interaction of ethnicity with classes of medications. The purpose of the present study was to review the literature and extract the results from a vast number of clinical trials that report on the effects of various antihypertensive medications on lowering BP. Literature research was done both on monodrug and combination drug therapies based on ethnicity and class/group of antihypertensive medications. The weighted average of medication effects provided by us may be used by other researchers as empirical values to correct measured systolic and diastolic BP for antihypertensive medication effects systematically according to the subject's therapy, the specific antihypertensive class/group used, and the ethnicity as well. The purpose was to provide a more systematic foundation for imputations of the untreated original BP.
Methods
All clinical trials published in English from 1969 to 2003 were searched in the PubMed database and information was extracted from each of them on the effects of antihypertensive medications. The search terms used included hypertension, efficacy, monodrug therapy, combination drug therapy, as well as the names of medication classes/ groups. We excluded clinical trials using multiple medications unless they reported the data for monodrug therapy also and whose duration was less than 4 weeks (except for loop diuretics for which 1 week is enough), and we also excluded combination drug studies in the absence of separate trials on the two component medications used. The BP was measured at trough in the morning before daily drug intake in the majority of reviewed clinical trials, or at the same time after medication in some of the other trials. Clinical trials were searched for the effects of medications used as monodrug therapy first. Because most of the 4416 prescriptions for BP-lowering medications used in the Hypertension Genetic Epidemiology Network (Hyper-GEN) Study 11 covered medications from only six major classes/groups of antihypertensive medications, we only focused on those groups including angiotensin-converting enzyme (ACE) inhibitors, ␣ 1 -blockers, cardioselective ␤-blockers (␤ 1 -blockers), calcium channel blockers, thiazide and thiazide-like diuretics, and loop diuretics (Table  A1 in Appendix A).
Within each of the classes/groups, the weighted average of medication effects was calculated separately by ethnicity based on the sample sizes of the clinical trials. The overall weighted average of medication effects was also estimated across all six major classes/groups, which may provide an approximate effect for other antihypertensive medications not covered here. The efficacy was first estimated using pooled dosage for each group of medications, and then dosage effects were explored for sitting and supine BPs. High or low dosage was defined for each trial based on its relative dose level among the clinical trials of each study medication (Tables A2 to A8 in Appendix A).
Clinical trials in which the doses of combination components were equivalent to those used in monodrug therapy, these were used to evaluate the effects of the combination drug therapy. The medication with the higher monodrug therapy effect in each of these clinical trials was designated by us as the first medication, and the other medication was considered as the second medication. The effect of the second medication was calculated as a percentage of the corresponding monodrug therapy effect:
␣ ϭ
Effect of combination drug therapy Ϫ Effect of 1st medication Effect of 2nd medication when used as monodrug therapy ϫ 100%
The effects of the second medications were estimated first separately for the combination drug therapies containing a thiazide diuretic or without any thiazide diuretic. Then, the overall weighted average effect of the second medication was calculated for each ethnicity. Combination drug therapies with more than two antihypertensive medications and also the effects of age and baseline BP on the response to the drugs were not considered in the present study.
Because some clinical trials included sitting BP and supine or standing BP measurements, we decided to use all studies based on sitting or supine BP measurements, and excluded any reports that were based on standing measurements of BP. This decision was based on an empirical finding in HyperGEN where sitting BP was more highly correlated with supine than with standing BP (eg, the correlation of the mean sitting with mean supine systolic BP was 0.90, n ϭ 4390, whereas that with mean standing BP was 0.83, n ϭ 4287). The efficacy reported in Tables 1 to 4, and in Tables A2 to A8 in Appendix A, represents the reductions in sitting (or supine) BP as compared to the placebo effect or baseline before the treatment.
Results
Tables A2 through A7 in Appendix A summarize results from 137 clinical trials on the effects of antihypertensive medications as monodrug therapy with commonly used dosage. A total of 10,405 participants were involved in these studies, with ages from 18 to 86 years, with diagnosis of mild-to-moderate hypertension. The clinical trials were mostly double-blinded, randomized, with the duration of the treatment varying from 1 week to 3 years.
The weighted average effects of monodrug therapy were calculated in two different ways separately by ethnicity, which are shown in Tables 1 to 3 : one includes clinical trials using sitting or supine BP (Table 1) , whereas the other Table was based on clinical trials using only sitting BP measurements ( Table 2 ). More trials were available when using sitting or supine BP measurements. As seen in Tables 1 and 2 , the two types of average effects were similar. The ACE inhibitors, ␣ 1 -blockers, and ␤ 1 -blockers were more effective as antihypertensive agents in non-African Americans than in African Americans (P Ͻ .0001, except for the effect of ␣ 1 -blockers on diastolic BP, with P ϭ .017). The reverse was found with calcium channel blockers, producing a greater reduction of BPs in African Americans than in non-African Americans (P Ͻ .001). When calcium channel blockers were divided into two groups, as dihydropyradine and non-dihydropyradine, the same pattern of the weighted average effects was shown across ethnicities. The non-dihydropyradine calcium channel blockers had lower effects on systolic BP in both non-African Americans and African Americans as compared to dihydropyradine medications (P Ͻ .0001), and higher effects on diastolic BP in non-African Americans (P Ͻ .0001). It was also observed that African Americans were more responsive to monodrug therapy with thiazide and loop diuretics in terms of both systolic and diastolic BP (P Ͻ .001). However, there was only one clinical trial in the literature reporting on the loop diuretics in African Americans, which included just 16 participants. Because most of the clinical trials on loop diuretics used supine BP measurement, this group of medications was not listed in Table 2 . The overall weighted average effect across the classes/groups of medications, when using sitting/supine BP measurements (Table 1) , on systolic BP in non-African Americans was higher than in African Americans (P Ͻ .0001), whereas the effect on diastolic BP was higher in African Americans (P Ͻ .0001). When the dose was increased, the BP responses to the antihpertensives improved, including ACE, calcium channel blockers, thiazide and thiazide-like diuretics, and loop diuretics ( Table  3 ). The overall responses did not improve with increased doses of ␣ 1 -blockers and ␤-blockers. We also noted that, as doses of medications increased, the racial difference in BP responses decreased for ACE and calcium channel blockers but increased for ␤-blockers and thiazides. The relatively limited number of clinical trials on combination drug therapy of different classes with different mechanisms of action are reported in Table A8 in Appendix A. We pooled several types of combination drug therapy together, including ACE inhibitors and calcium channel blockers, diuretics and ACE inhibitors, ␣ 1 -blockers and calcium channel blockers, and diuretics and angiotensin II antagonist. When the components of the combination drug therapy used the same dosages as in the corresponding monotherapies, the combination drug therapy was generally more effective than either of the monotherapies for systolic and diastolic BP. Most of them had less than additive effects, although some showed synergistic effects on treatment of hypertension. The medication with higher effect on BP (from monodrug therapy trials) in the combination was considered as the first medication, and the one with lower effect as the second one. The effect of the second medication, calculated as a percentage of the corresponding monodrug therapy effect, ranged from an actual increase of 5% to a decrease of 143% in systolic BP, and an increase of 18% to a decrease of 135% in diastolic BP. Values larger than 100% indicate a synergistic effect of combining two different classes of antihypertensive medications.
The weighted average effect of the second medication was calculated from 28 reported clinical trials with a total sample size of 1334 participants ( Table 4) . The average percentage effect of the second medication across ethnicities was 84% and 65% for systolic and diastolic BP, respectively. These values for non-African American subjects were much lower (52% and 50%, respectively). African Americans were more responsive to combination drug therapy than non-African Americans, with 129% and 71% as the average percent effect of the second medication (P Ͻ .0001). When the combinations were separated based on whether or not they included a diuretic, the combinations containing a diuretic had higher average percentage effects for the second drugs across ethnicities (P Ͻ .0001). To correct the measured sitting or supine BPs in whites taking ACE inhibitor and a thiazide diuretic, for example, the net effect of the combination drug therapy can be estimated as follows without considering dosage:
Estimated effect on systolic BP thiazide diurectic ϩ ACE inhibitor ϭ 15.0 ϩ 14.3 ϫ 53% ϭ 22.6 (mm Hg) Estimated effect on diastolic BP ACE inhibitor ϩ thiazide diurectic ϭ 10.4 ϩ 9.5 ϫ 44% ϭ 14.6 (mm Hg), where 15.0 mm Hg is the effect on systolic BP of the first drug in the combination, thiazide diuretics, in whites; 14.3 mm Hg is the effect on systolic BP of the second drug, ACE inhibitors, when used as monotherapy in whites; and 53% is the percentage of effect that the second drug contributes to the combination therapy. For diastolic BP, the first drug is ACE inhibitor with an effect of 10.4 mm Hg, and the thiazide diuretic is the second drug that contributes 44% of its effect (9.5 mm Hg) ( Table 1) . 
Discussion
The goals of treatment for hypertension are to optimally control high BP and to reduce associated cardiovascular and renal morbidity and mortality. 12 Blood pressure control cannot always be achieved with a single agent; many patients require combination drug therapy with two or more agents to attain BP less than 140/90 mm Hg. 1 In this study, information was extracted from many clinical trials that reported on the effect of antihypertensive medications on BP. Using these results, we have estimated the average effects on BP of different classes/groups of medications separately by ethnicity. These estimates may be used to impute the original unmedicated BPs of participants using antihypertensive therapy. We recognize the limitations of using group averages to predict individual responses, but prediction of individual measurements does not appear to be feasible.
A meta-analysis of clinical trials on the efficacy of antihypertensive medications was performed by Law et al. 13 They studied five groups of antihypertensive medications, including thiazides, ␤-blockers, ACE inhibitors, angiotensin II, and calcium channel blockers. They concluded that the BP-lowering effects of these classes of medications were similar, with an average reduction of 9.1 mm Hg systolic and 5.5 mm Hg diastolic at standard doses. The present study also demonstrated that, when the ethic groups were pooled, the medications in the six major classes/groups used in monodrug therapy had approximately similar effects. However, there were clear differences between African Americans and non-African Americans. For example, ␤-blockers were shown to be less effective than thiazide diuretics in African American patients. Hypertensive African Americans are considered to exhibit higher plasma volumes, reflected in lower plasma renin activities, than hypertensive whites. 14, 15 It was postulated that patients with low plasma renin activity have a "volume-dependent" form of hypertension that will respond to diuretic therapy, whereas patients with higher plasma renin activity, and presumably lower plasma volume, may be more responsive to ␤-blockers. 16 Therefore, we suggest that the ethnic-specific medication effects estimated should be considered for these drug categories due to the differential ethnic responses. The effects estimated by combining the races should be used for loop diuretics because of the small race-specific sample sizes for loop diuretics.
Law et al 13 concluded that the effects of combination medications were additive. However, based on our review of the clinical trials, combination medications were found to be less effective than the sum of the two medication effects. In addition, the combination medications responded better than either medication used alone. For instance, the combination of ACE inhibitor and thiazide diuretic was shown to have advantages over the two monodrug therapies (Table A8 ). The ACE inhibitors block the counter-regulatory increase in the angiotensin II trig- No clinical trials were reviewed in African Americans for ␣-blockers and loop diuretics with relative high dosage. Abbreviations as in Table 1 .
* Lists the class or group of antihypertensive medications along with an Appendix table (in parentheses) that provides the details of individual clinical trials. For example, see Table A2 in the Appendix A for ACE inhibitors.
gered by diuretic therapy; conversely, thiazide diuretics may stimulate the renin-angiotensin system and enhance the antihypertensive action of ACE inhibitors. 17, 18 Generally, patients who do not respond adequately to ACE inhibitor monodrug therapy often do respond to the combination drug therapy. For purposes of imputing the original untreated BP, in combination drug therapy, the effect of the first medication can be used in the same way as monodrug therapy, and the effect of the second medication should be adjusted with the percent effects shown in Table  4 . We suggest that ethnic-specific percentages may be used for non-African Americans, whereas the overall percentages should be used for African Americans due to small samples available.
The process of imputing original untreated BP measurements for subjects under antihypertensive medications is a complicated process. Our study has some potential limitations. First, we focused on six classes/groups that were commonly used in hypertension treatment. During the imputation of pretreatment BP (if no other sources are available), we suggest that the overall weighted average effect of the six classes/groups be used as an (approximate) average effect for the other classes or groups of antihypertensive medications not covered in our study. Second, in our study, clinical trials with different doses were pooled together to estimate the general efficacy for each class/ group. The efficacy of the six study classes/groups may be influenced by the doses chosen. We assumed that these trials used the most commonly recommended doses. Third, poor adherence to antihypertensive therapy is always a major therapeutic problem leading to the lack of adequate control in large sections of patients with hypertension. 19 Although, noncompliance may not be uniform across drug classes or different populations, various strategies have been implemented by the clinical trials to improve significantly compliance during the clinical trials. Therefore the efficacy obtained from the clinical trials may be higher than that in the general hypertensive population under treatment.
In summary, our study provides a summary of the effects on BP of different antihypertensive medications used in controlled clinical trials. The average effects grouped by class/group and ethnicity as monodrug or combination drug therapy and the overall averages can be used in imputing original pretreatment BP levels. The imputed BPs can be used in epidemiologic and genetic analyses in which a more precise estimation of the phenotype is required to improve the power of the study.
Perspectives
Prediction of pretreatment BP in individuals on antihypertensive medications is useful for epidemiologic and genetic analysis. For individuals on monodrug therapy to control BP, the original untreated BP may be calculated simply by adding the medication effect (of a specific class/group of medications and ethnicity) to the measured BP. For individuals on combination drug therapy, the measured BPs may be corrected by first adding the monodrug therapy effect of the first medication with the highest effect, plus the weighted average effect of the second medication. As a general case, the overall weighted average of medication effects can be used to correct the effects of the medications not belonging to the classes we focused here.
mm Hg in 3727 subjects. For thiazide and loop diuretics, hydrochlorothiazide and furosemide were commonly used in clinical trials (Tables A6 and A7 ). Based on the clinical trials, systolic BP decreased from 5.4 mm Hg (sitting BP) to 25.0 mm Hg (supine BP) with hydrochlorothiazide and 3.0 mm Hg (sitting BP) to 34.0 mm Hg (sitting BP) with furosemide, whereas the corresponding decrease in diastolic BP was 3.0 mm Hg (sitting BP) to 18.0 mm Hg (supine BP) and 0.0 mm Hg (supine/sitting BP) to 18.0 mm Hg (sitting BP). These tables, along with citations for all individual clinical trials, may be found on the following website: http://www.biostat. wustl.edu/hypergen/publications.html.
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